Company research
ABEONA THERAPEUTICS INC.
CIK 318306Updated Sep 24, 2026
SecurityABEO · NASDAQ · equity
Historical securities (1)
ABEOW · NASDAQ · warrant · closed Dec 23, 2019Name history
PLASMATECH BIOPHARMACEUTICALS INC · through Jun 4, 2015ACCESS PHARMACEUTICALS INC · through Aug 14, 2014CHEMEX PHARMACEUTICALS INC · through Feb 5, 1996
ABEO price & chart
Loading TradingView…
NASDAQ:ABEO on TradingView ↗About the company
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
In the news
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN® ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO ↗
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) ↗
Seeking Alpha
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity ↗
Abeona outlines shift to patient-treated and net revenue reporting while targeting 85%-90% steady-state gross margins ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 219,570,000Source | 108,931,000Source | 64,002,000Source | 64,214,000Source |
| Property, Plant and Equipment, NetUSD | 9,921,000Source | 4,430,000Source | 3,533,000Source | 5,741,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 78,437,000Source | 23,357,000Source | 14,473,000Source | 14,217,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 6,147,000Source | — | — | — |
| Inventory, NetUSD | 5,493,000Source | — | — | — |
| Assets, CurrentUSD | 204,906,000Source | 100,853,000Source | 55,737,000Source | 53,099,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,294,000Source | 1,143,000Source | 729,000Source | 424,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,962,000Source | 3,552,000Source | 4,455,000Source | 5,331,000Source |
| Other Assets, NoncurrentUSD | 781,000Source | 96,000Source | 277,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 60,354,000Source | 64,900,000Source | 49,176,000Source | 37,453,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 550,000Source | 457,000Source | 265,000Source | 177,000Source |
| Additional Paid in CapitalUSD | 900,603,000Source | 856,824,000Source | 764,151,000Source | 722,049,000Source |
| Retained Earnings (Accumulated Deficit)USD | -742,075,000Source | -813,258,000Source | -749,524,000Source | -695,336,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 138,000Source | 8,000Source | -66,000Source | -129,000Source |
| Stockholders' Equity Attributable to ParentUSD | 159,216,000Source | 44,031,000Source | 14,826,000Source | 26,761,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 7,000,000Source |
| Liabilities and EquityUSD | 219,570,000Source | 108,931,000Source | 64,002,000Source | 64,214,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 29,570,000Source | 16,587,000Source | 13,422,000Source | 7,779,000Source |
| Operating Lease, Liability, CurrentUSD | 864,000Source | 823,000Source | 998,000Source | 1,773,000Source |
| Accounts Payable, CurrentUSD | 7,889,000Source | 3,441,000Source | 1,858,000Source | 1,811,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,069,000Source | 3,262,000Source | 4,402,000Source | 5,854,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | 3Source | — | — | — |
| Accrued Liabilities, CurrentUSD | 8,467,000Source | 6,333,000Source | 5,985,000Source | 3,991,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 98,100,000Source | 52,600,000Source | 52,500,000Source |
| Deferred Tax Liabilities, NetUSD | 1,604,000Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 12,222,000Source | 5,926,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 7,813,000Source | 13,037,000Source | — | — |
| Short-term InvestmentsUSD | 112,967,000Source | 74,363,000Source | 37,753,000Source | 37,932,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,549,000Source | 2,004,000Source | 2,288,000Source | 3,093,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,779,000Source | 6,628,000Source | 4,768,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 6,147,000Source | — | — | -3,000,000Source |
| Increase (Decrease) in InventoriesUSD | 5,493,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -76,326,000Source | -56,015,000Source | -37,009,000Source | -43,483,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 105,028,000Source | -39,240,000Source | 208,000Source | -23,964,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 7,975,000Source | 2,446,000Source | 331,000Source | 130,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 26,040,000Source | 104,139,000Source | 37,057,000Source | 43,173,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 54,742,000Source | 8,884,000Source | 256,000Source | -24,274,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 78,437,000Source | 23,695,000Source | 14,811,000Source | 14,555,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,589,000Source | 2,670,000Source | — | — |
| Income Taxes Paid, NetUSD | — | 7,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,779,000Source | 6,628,000Source | 4,768,000Source | 3,051,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 98,100,000Source | 52,600,000Source | 52,500,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 2,000Source | -47,000Source | -138,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | 292,000Source |
| General and Administrative ExpenseUSD | 65,031,000Source | 29,851,000Source | 19,004,000Source | 17,256,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 1,355,000Source |
| Income Tax Expense (Benefit)USD | 100,000Source | — | — | — |
| Inventory Write-downUSD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | 71,183,000Source | -63,734,000Source | -54,188,000Source | -39,696,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -63,700,000Source | -54,188,000Source | -43,478,000Source |
| Nonoperating Income (Expense)USD | 410,000Source | 1,194,000Source | 2,943,000Source | — |
| Operating ExpensesUSD | — | 64,211,000Source | 50,635,000Source | 52,329,000Source |
| Operating Lease, ExpenseUSD | 1,700,000Source | 1,300,000Source | 1,200,000Source | — |
| Operating Lease, Impairment LossUSD | — | — | -1,065,000Source | 2,511,000Source |
| Proceeds from Issuance of Common StockUSD | 17,300,000Source | 15,475,000Source | 14,408,000Source | 12,839,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | 20,000,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 5,820,000Source | — | 3,500,000Source | 1,414,000Source |
| Cost of RevenueUSD | 1,532,000Source | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 65,031,000Source | — | — | — |
| Operating Income (Loss)USD | -89,448,000Source | -64,211,000Source | -47,135,000Source | -50,915,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 71,283,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 100,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | 71,183,000Source | -63,734,000Source | -54,188,000Source | -39,696,000Source |
| Earnings Per Share, BasicUSD per share | 1.34Source | -1.55Source | -2.53Source | -5.53Source |
| Earnings Per Share, DilutedUSD per share | 1.01Source | -1.55Source | -2.53Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 52,952,917Source | 41,048,206Source | 21,380,476Source | 7,861,515Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 66,135,821Source | 41,048,206Source | 21,380,476Source | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 95,268,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | 100,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,500,000Source | 2,000,000Source | 2,300,000Source | 3,100,000Source |
| General and Administrative ExpenseUSD | 65,031,000Source | 29,851,000Source | 19,004,000Source | 17,256,000Source |
| Interest ExpenseUSD | 3,740,000Source | 4,208,000Source | 418,000Source | 736,000Source |
| Interest Income, OperatingUSD | 5,556,000Source | 4,246,000Source | 2,117,000Source | 431,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -63,700,000Source | -54,188,000Source | -43,478,000Source |
| Nonoperating Income (Expense)USD | 410,000Source | 1,194,000Source | 2,943,000Source | — |
| Operating ExpensesUSD | — | 64,211,000Source | 50,635,000Source | 52,329,000Source |
| Operating Lease, ExpenseUSD | 1,700,000Source | 1,300,000Source | 1,200,000Source | — |
| Other Operating IncomeUSD | — | — | — | 141,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | 3,782,000Source |
| Research and Development ExpenseUSD | 26,812,000Source | 34,360,000Source | 31,091,000Source | 28,965,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million - - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed - - Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process - - $146.8 million i…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update - Three patients treated with ZEVASKYN ® in Q1 2026 - -QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-07
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors CLEVELAND, April 7, 2026 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona’s Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly t…
Read attachment ↗